Abstract: Are disclosed new crystalline forms of asenapine maleate, useful in the production of pharmaceutical formulations for the treatment of diseases of the central nervous system, in particular schizophrenia; processes for the production of these new crystalline forms are also disclosed.

Abstract: Are disclosed new crystalline forms of asenapine maleate, useful in the production of pharmaceutical formulations for the treatment of diseases of the central nervous system, in particular schizophrenia; processes for the production of these new crystalline forms are also disclosed.

Abstract: The present invention relates to a novel one step process for preparing cross-linked poly(allylamine) polymers or salts thereof using the novel cross-linking agent of Formula (IV). This invention also relates to the compound of Formula (IV) as well as to a process to obtain it. The cross-linked poly(allylamine) polymers of the invention are useful in medicine as substrate-binding polymers.

Abstract: The invention relates to novel crystalline forms of fexofenadine base, a process for the preparation thereof and the use thereof in therapy.

Abstract: The present invention relates to a novel one step process for preparing cross-linked poly(allylamine) polymers or salts thereof using the novel cross-linking agent of Formula (IV). This invention also relates to the compound of Formula (IV) as well as to a process to obtain it. The cross-linked poly(allylamine) polymers of the invention are useful in medicine as substrate-binding polymers.

Abstract: Ziprasidone base or a pharmaceutically acceptable salt thereof free from colored impurities, in particular those giving the product a “slightly pink to pink” coloration.

Abstract: Ziprasidone base or a pharmaceutically acceptable salt thereof free from colored impurities, in particular those giving the product a “slightly pink to pink” coloration.

Abstract: The invention provides novel crystalline forms of fexofenadine hydrochloride, a process for the preparation of the novel forms and of the known form A, and their use in therapy.

Abstract: A process for preparation of a compound of formula (I), both as the isomeric mixture and individual isomers, wherein Q is ?CR8— or ?N—; each R1, R2, R3, R4 is independently selected from hydrogen, halogen, hydroxy; nitro; C1-C6 alkyl optionally substituted with hydroxy; alkylthio C1-C6; C1-C6 alkoxy optionally substituted with halogen or C1-C6 alkoxy; phenyl-C1-C6 alkyl; phenyl-C1-C6 alkoxy; and —N(RaRb) wherein each Ra and Rb is independently hydrogen or C1-C6 alkyl or Ra and Rb, taken together with the nitrogen atom they are linked to, form a saturated heterocyclic ring; and each R5, R6, R7, R8 is independently selected from hydrogen, halogen, hydroxy; C1-C6 alkyl optionally substituted with hydroxy; alkylthio C1-C6; C1-C6 alkoxy optionally substituted with halogen; C1-C6 alkyl-carbonyl, C1-C6 alkoxy-carbonyl, and oxazol-2-yl; comprising converting a compound of formula (IV), to said compound of formula (I), in the presence of a catalyst, if necessary in an organic solvent.

Abstract: New crystalline form of ziprasidone hydrochloride hemihydrate, process for its preparation, its use for the purification of ziprasidone, its pharmaceutical compositions and their use in therapy.

Abstract: Protriptyline hydrochloride crystalline Form B, a process for its preparation, a pharmaceutical composition containing it the use thereof.

Abstract: Crystalline forms of imiquimod, a process for the preparation thereof and the use thereof in the purification of imiquimod.

Abstract: Novel crystalline form of fosinopril calcium, process for its preparation, pharmaceutical compositions and use thereof in therapy.

Abstract: Losartan potassium crystalline Form ?, a process for its preparation, a pharmaceutical composition therefrom, its use in therapy and in a purification process of losartan potassium.

Abstract: Ziprasidone base or a pharmaceutically acceptable salt thereof free from colored impurities, in particular those giving the product a “slightly pink to pink” coloration.

Abstract: Rabeprazole sodium in crystalline hydrate forms, a pharmaceutical composition containing them, their use in therapy, a process for their preparation, and the use thereof for the purification of rabeprazole sodium.

Abstract: Novel adapalene crystalline and amorphous Forms, processes for the preparation thereof, their use for the purification of adapalene, pharmaceutical compositions containing the forms and the use thereof in therapy.

Abstract: The invention relates to novel crystalline forms of fexofenadine base, a process for the preparation thereof and the use thereof in therapy.

Abstract: The invention provides novel crystalline forms of fexofenadine hydrochloride, a process for the preparation of the novel forms and of the known form A, and their use in therapy.

Abstract: Novel crystalline forms of pantoprazole sodium salt solvate with ketone solvents, a process for the preparation thereof, the use of the forms for the purification of pantoprazol, pharmaceutical compositions therefrom and the use thereof in therapy.